Skip to content
ClinCalc Pro
Menu
Hypoglycaemia Antidote / Endocrine Agent Pregnancy: Can be used during pregnancy (does not cross the placental barrier; no known harmful effects). Can be used during breast-feeding.

Glucagon

Brand names: GlucaGen, Baqsimi (nasal powder)

A pancreatic hormone given parenterally as emergency treatment for severe hypoglycaemia, and also used to relax smooth muscle for certain radiological procedures.

Auto-extracted from the source labelling — not yet independently clinician-verified. These values were distilled from the UK SPC (or the US label where noted) but have not had a clinician sign-off. Confirm against the current SmPC before prescribing.

Adult dose

Dose: 1 mg
Route: Subcutaneous or intramuscular injection
Frequency: Single dose; if no response within 10 minutes give intravenous glucose
Severe hypoglycaemia (therapeutic indication), adult patients: administer 1 mg SC or IM. Patient normally responds within 10 minutes; when responsive, give oral carbohydrate to restore liver glycogen and prevent relapse. If no response within 10 minutes, give intravenous glucose. Glucagon has little or no effect when liver glycogen is depleted (prolonged fasting, adrenal insufficiency, chronic or alcohol-induced hypoglycaemia). Paediatric (severe hypoglycaemia): 0.5 mg for children below 25 kg or younger than 6–8 years; 1 mg for children above 25 kg or older than 6–8 years. Dissolve powder in accompanying solvent immediately before use; do NOT give as an IV infusion. Second (diagnostic) indication — inhibition of GI motility, adults: 0.2–0.5 mg IV or 1 mg IM to relax stomach/duodenum/small bowel; 0.5–0.75 mg IV or 1–2 mg IM to relax colon (administered by medical personnel).

Dose adjustments

Renal

Can be used in patients with renal and hepatic impairment (no dose adjustment stated).

Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

  • Hypersensitivity to glucagon or to any of the excipients
  • Phaeochromocytoma

Side effects

  • Nausea
  • Vomiting
  • Abdominal pain
  • Hypersensitivity reactions including anaphylactic reaction/shock (very rare)
  • Injection site reactions

Interactions

  • Insulin — acts antagonistically to glucagon
  • Indomethacin — glucagon may lose its ability to raise blood glucose, or may produce hypoglycaemia
  • Warfarin — glucagon may increase the anticoagulant effect
  • Beta-blockers — transient increase in pulse and blood pressure

Clinical monograph

How it works

Glucagon stimulates hepatic glycogenolysis and gluconeogenesis to raise blood glucose, an effect that depends on adequate hepatic glycogen stores.

Prescribing in practice

  • The most important safety point is that glucagon is ineffective when hepatic glycogen is depleted (for example in starvation, prolonged hypoglycaemia, chronic alcohol use, or adrenal insufficiency), so oral or intravenous glucose must follow once the patient can swallow or access allows.
  • After recovery, give oral carbohydrate to replenish glycogen and prevent recurrent hypoglycaemia.
  • Use with caution in phaeochromocytoma, insulinoma, and glucagonoma.

Monitoring

Monitor blood glucose and conscious level after administration, ensuring the patient eats carbohydrate once able and is observed for recurrence.

Counselling the patient

  • Family or carers should be trained to recognise severe hypoglycaemia and to give the injection.
  • After it works, eat a carbohydrate snack as soon as you can swallow safely.
  • Always seek follow-up, as nausea and vomiting are common afterwards and low glucose can recur.

Evidence & guidelines

Glucagon is recommended for out-of-hospital treatment of severe hypoglycaemia in people with diabetes by NICE and national diabetes guidance.

Reference: JBDS Hypoglycaemia Guidelines 2018; NICE NG17; Baqsimi SPC (Eli Lilly); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.